Molecular Characteristics of Rifampin-Sensitive and -Resistant Isolates and Characteristics of rpoB Gene Mutations in Methicillin-Resistant Staphylococcus aureus. 2021

Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.

BACKGROUND Methicillin-resistant Staphylococcus aureus (MRSA) infections have become a leading cause of severe infections in both healthcare and community settings. Mutations in the rpoB gene cause resistance to rifampin (RIFR), a critical antibiotic for the treatment of multidrug-resistant Staphylococcus aureus. The aim of this study was to detect the molecular characteristics of RIFR MRSA and analyze the rpoB gene mutations involved in RIF resistance. METHODS A total of 49 RIFR MRSA and 38 RIFS MRSA isolates collected from seven cities in China were analyzed by multilocus sequence typing, staphylococcus chromosomal cassette mec (SCCmec) typing, spa typing, and rpoB gene mutations. RESULTS ST239-III-t030 (35/49, 71.4%), the major clone in RIFR MRSA isolates; ST45-IV-t116 (16/38, 42.1%), the major clone in RIFS MRSA isolates with rpoB mutations. RIFR MRSA isolates were resistant to erythromycin, ciprofloxacin, tetracycline, gentamicin, and clindamycin. By contrast, RIFS MRSA isolates with rpoB mutation were more susceptible to ciprofloxacin, tetracycline, and gentamicin. Forty-three (87.8%) isolates present the mutational change H481N and L466S, conferring 128-512 μg/mL RIF resistance. The four isolates with RIF MIC ≥ 1024 μg/mL had additional amino acid substitution: H481N, L466S, A473T (n=2); H481Y (n=2), associated with a high-level RIF resistance. Of 38 RIFS MRSA isolates, two mutations were observed, including H481N (n=37) and A477D (n=1). CONCLUSIONS In conclusion, the predominant RIFR MRSA clones in China were ST239-III-t030. Molecular characteristics, antibiotic-resistant profiles, and rpoB mutations between RIFR MRSA and RIFS MRSA were diverse. Antibiotics for treating patients with MRSA infections can be selected based on molecular characteristics.

UI MeSH Term Description Entries

Related Publications

Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
November 1999, Antimicrobial agents and chemotherapy,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
September 2015, The Indian journal of medical research,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
September 2006, Journal of clinical microbiology,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
October 1998, Antimicrobial agents and chemotherapy,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
July 2004, Antimicrobial agents and chemotherapy,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
December 2020, Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
May 2011, Journal of clinical microbiology,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
December 2011, Pathologie-biologie,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
August 2020, Antimicrobial resistance and infection control,
Yinjuan Guo, and Bingjie Wang, and Lulin Rao, and Xinyi Wang, and Huilin Zhao, and Meilan Li, and Fangyou Yu
April 2009, The new microbiologica,
Copied contents to your clipboard!